Recombinant zoster vaccine in immunocompetent and immunocompromised adults: A review of clinical studies

References

• Cohen JI, Solomon CG. Herpes zoster. N Engl J Med. 2013;369(3):255–13. doi:10.1056/NEJMcp1302674.
   PubMed Web of Science ®Google Scholar
• Gilden D, Cohrs RJ, Mahalingam R, Nagel MA. Varicella zoster virus vasculopathies: diverse clinical manifestations, laboratory features, pathogenesis, and treatment. Lancet Neurol. 2009;8(8):731–40. doi:10.1016/S1474-4422(09)70134-6.
   PubMed Web of Science ®Google Scholar
• Bahouth MN, Venkatesan A. Acute viral illnesses and ischemic stroke: pathophysiological considerations in the era of the COVID-19 pandemic. Stroke. 2021;52(5):1885–94. doi:10.1161/STROKEAHA.120.030630.
   PubMed Web of Science ®Google Scholar
• Johnson RW. Herpes zoster and postherpetic neuralgia. Expert Rev Vaccines. 2010;9(3 Suppl):21–6. doi:10.1586/erv.10.30.
   PubMed Web of Science ®Google Scholar
• Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4(6):e004833. doi:10.1136/bmjopen-2014-004833.
   PubMed Web of Science ®Google Scholar
• McKay SL, Guo A, Pergam SA, Dooling K. Herpes zoster risk in immunocompromised adults in the United States: a systematic review. Clin Infect Dis. 2020;71(7):e125–34. doi:10.1093/cid/ciz1090.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. ACIP evidence to recommendations framework for use of recombinant zoster vaccine in immunocompromised adults aged ≥19 years; 2023 [accessed 2023 Feb]. https://www.cdc.gov/vaccines/acip/recs/grade/recombinant-zoster-immunocompromised-etr.html.
   Google Scholar
• Yun H, Yang S, Chen L, Xie F, Winthrop K, Baddley JW, Saag KG, Singh J, Curtis JR. Risk of herpes zoster in autoimmune and inflammatory diseases: implications for vaccination. Arthritis Rheumatol. 2016;68(9):2328–37. doi:10.1002/art.39670.
   PubMed Web of Science ®Google Scholar
• Batram M, Witte J, Schwarz M, Hain J, Ultsch B, Steinmann M, Bhavsar A, Wutzler P, Criée CP, Hermann C, et al. Burden of herpes zoster in adult patients with underlying conditions: analysis of German claims data, 2007–2018. Dermatol Ther (Heidelb). 2021;11(3):1009–26. doi:10.1007/s13555-021-00535-7.
   PubMed Web of Science ®Google Scholar
• Gershon AA, Breuer J, Cohen JI, Cohrs RJ, Gershon MD, Gilden D, Grose C, Hambleton S, Kennedy PG, Oxman MN, et al. Varicella zoster virus infection. Nat Rev Dis Primers. 2015;1:15016. doi:10.1038/nrdp.2015.16.
   PubMed Web of Science ®Google Scholar
• Mbinta JF, Nguyen BP, Awuni PMA, Paynter J, Simpson CR. Post-licensure zoster vaccine effectiveness against herpes zoster and postherpetic neuralgia in older adults: a systematic review and meta-analysis. Lancet Healthy Longev. 2022;3(4):e263–75. doi:10.1016/s2666-7568(22)00039-3.
   PubMedGoogle Scholar
• Anderson TC, Masters NB, Guo A, Shepersky L, Leidner AJ, Lee GM, Kotton CN, Dooling KL. Use of recombinant zoster vaccine in immunocompromised adults aged ≥19 years: recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(3):80–4. doi:10.15585/mmwr.mm7103a2.
   PubMed Web of Science ®Google Scholar
• Harbecke R, Cohen JI, Oxman MN. Herpes zoster vaccines. J Infect Dis. 2021;224(12 Suppl 2):S429–42. doi:10.1093/infdis/jiab387.
   PubMedGoogle Scholar
• GlaxoSmithKline Biologicals. Shingrix (zoster vaccine recombinant, adjuvanted) suspension for intramuscular injection - Highlights of Prescribing Information; Revised 2021 Jul [ accessed 2022 Oct]. https://www.fda.gov/media/108597/download.
   Google Scholar
• Merck Sharp and Dohme B.V. Zostavax (zoster vaccine live, attenuated) suspension for subcutaneous or intramuscular injection - Highlights of Prescribing Information; [ accessed 2022 Oct]. https://www.fda.gov/media/82524/download.
   Google Scholar
• Tavares-Da-Silva F, Co MM, Dessart C, Hervé C, López-Fauqued M, Mahaux O, Van Holle L, Stegmann JU. Review of the initial post-marketing safety surveillance for the recombinant zoster vaccine. Vaccine. 2020;38(18):3489–500. doi:10.1016/j.vaccine.2019.11.058.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Shingrix EPAR - Product Information; Last updated 2021 Oct 13 [accessed 2022 Oct]. https://www.ema.europa.eu/documents/product-information/shingrix-epar-product-information_en.pdf.
   Google Scholar
• Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, Levin MJ, McElhaney JE, Poder A, Puig-Barberà J, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087–96. doi:10.1056/NEJMoa1501184.
   PubMed Web of Science ®Google Scholar
• Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Díez-Domingo J, Godeaux O, Levin MJ, McElhaney JE, Puig-Barberà J, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375(11):1019–32. doi:10.1056/NEJMoa1603800.
   PubMed Web of Science ®Google Scholar
• Kovac M, Lal H, Cunningham AL, Levin MJ, Johnson RW, Campora L, Volpi A, Heineman TC. Complications of herpes zoster in immunocompetent older adults: incidence in vaccine and placebo groups in two large phase 3 trials. Vaccine. 2018;36(12):1537–41. doi:10.1016/j.vaccine.2018.02.029.
   PubMed Web of Science ®Google Scholar
• Willer DO, Oostvogels L, Cunningham AL, Gervais P, Gorfinkel I, Hyung Kim J, Talarico C, Wascotte V, Zahaf T, Colindres R, et al. Efficacy of the adjuvanted recombinant zoster vaccine (RZV) by sex, geographic region, and geographic ancestry/ethnicity: a post-hoc analysis of the ZOE-50 and ZOE-70 randomized trials. Vaccine. 2019;37(43):6262–7. doi:10.1016/j.vaccine.2019.09.028.
   PubMed Web of Science ®Google Scholar
• Curran D, Andrew MK, Levin MJ, Turriani E, Matthews S, Fogarty C, Klein NP, Grupping K, Oostvogels L, Schmader KE. Evaluation of two frailty indices, with practical application in a vaccine clinical trial. Hum Vaccin Immunother. 2019;15(12):2960–8. doi:10.1080/21645515.2019.1622974.
   PubMed Web of Science ®Google Scholar
• Curran D, Kim JH, Matthews S, Dessart C, Levin MJ, Oostvogels L, Riley ME, Schmader KE, Cunningham AL, McNeil SA, et al. Recombinant zoster vaccine is efficacious and safe in frail individuals. J Am Geriatr Soc. 2021;69(3):744–52. doi:10.1111/jgs.16917.
   PubMed Web of Science ®Google Scholar
• Andrew MK, Matthews S, Kim JH, Riley ME, Curran D. An easy-to-implement clinical-trial frailty index based on accumulation of deficits: validation in zoster vaccine clinical trials. Clin Interv Aging. 2022;17:1261–74. doi:10.2147/cia.S364997.
   PubMed Web of Science ®Google Scholar
• Oostvogels L, Heineman TC, Johnson RW, Levin MJ, McElhaney JE, Van den Steen P, Zahaf T, Dagnew AF, Chlibek R, Diez-Domingo J, et al. Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials. Hum Vaccin Immunother. 2019;15(12):2865–72. doi:10.1080/21645515.2019.1627818.
   PubMed Web of Science ®Google Scholar
• Dagnew AF, Rausch D, Hervé C, Zahaf T, Levin MJ, Schuind A. Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials. Rheumatology (Oxford). 2021;60(3):1226–33. doi:10.1093/rheumatology/keaa424.
   PubMed Web of Science ®Google Scholar
• Boutry C, Hastie A, Diez-Domingo J, Tinoco JC, Yu CJ, Andrews C, Beytout J, Caso C, Cheng HS, Cheong HJ, et al. The adjuvanted recombinant zoster vaccine confers long-term protection against herpes zoster: interim results of an extension study of the pivotal phase 3 clinical trials ZOE-50 and ZOE-70. Clin Infect Dis. 2022;74(8):1459–67. doi:10.1093/cid/ciab629.
   PubMed Web of Science ®Google Scholar
• Strezova A, Diez-Domingo J, Al Shawafi K, Tinoco JC, Shi M, Pirrotta P, Mwakingwe-Omari A. Long-term protection against herpes zoster by the adjuvanted recombinant zoster vaccine: interim efficacy, immunogenicity, and safety results up to 10 years after initial vaccination. Open Forum Infect Dis. 2022;9(10):ofac485. doi:10.1093/ofid/ofac485.
   PubMed Web of Science ®Google Scholar
• Bastidas A, de la Serna J, El Idrissi M, Oostvogels L, Quittet P, López-Jiménez J, Vural F, Pohlreich D, Zuckerman T, Issa NC, et al. Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial. JAMA. 2019;322(2):123–33. doi:10.1001/jama.2019.9053.
   PubMed Web of Science ®Google Scholar
• Dagnew AF, Ilhan O, Lee WS, Woszczyk D, Kwak JY, Bowcock S, Sohn SK, Rodriguez Macías G, Chiou TJ, Quiel D, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. Lancet Infect Dis. 2019;19(9):988–1000. doi:10.1016/s1473-3099(19)30163-x.
   PubMed Web of Science ®Google Scholar
• Vink P, Shiramoto M, Ogawa M, Eda M, Douha M, Heineman T, Lal H. Safety and immunogenicity of a herpes zoster subunit vaccine in Japanese population aged ≥50 years when administered subcutaneously vs. intramuscularly. Hum Vaccin Immunother. 2017;13(3):574–8. doi:10.1080/21645515.2016.1232787.
   PubMed Web of Science ®Google Scholar
• Cunningham AL, Heineman TC, Lal H, Godeaux O, Chlibek R, Hwang SJ, McElhaney JE, Vesikari T, Andrews C, Choi WS, et al. Immune responses to a recombinant glycoprotein E herpes zoster vaccine in adults aged 50 years or older. J Infect Dis. 2018;217(11):1750–60. doi:10.1093/infdis/jiy095.
   PubMed Web of Science ®Google Scholar
• Lal H, Poder A, Campora L, Geeraerts B, Oostvogels L, Vanden Abeele C, Heineman TC. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: results of a phase III, randomized, open-label, multicenter study. Vaccine. 2018;36(1):148–54. doi:10.1016/j.vaccine.2017.11.019.
   PubMed Web of Science ®Google Scholar
• Dagnew AF, Klein NP, Hervé C, Kalema G, Di Paolo E, Peterson J, Salaun B, Schuind A. The adjuvanted recombinant zoster vaccine in adults aged ≥65 years previously vaccinated with a live-attenuated herpes zoster vaccine. J Infect Dis. 2021;224(7):1139–46. doi:10.1093/infdis/jiaa083.
   PubMed Web of Science ®Google Scholar
• Godeaux O, Kovac M, Shu D, Grupping K, Campora L, Douha M, Heineman TC, Lal H. Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ≥ 50 years of age with a prior history of herpes zoster: a phase III, non-randomized, open-label clinical trial. Hum Vaccin Immunother. 2017;13(5):1051–8. doi:10.1080/21645515.2016.1265715.
   PubMed Web of Science ®Google Scholar
• Hastie A, Catteau G, Enemuo A, Mrkvan T, Salaun B, Volpe S, Smetana J, Rombo L, Schwarz T, Pauksens K, et al. Immunogenicity of the adjuvanted recombinant zoster vaccine: persistence and anamnestic response to additional doses administered 10 years after primary vaccination. J Infect Dis. 2021;224(12):2025–34. doi:10.1093/infdis/jiaa300.
   PubMed Web of Science ®Google Scholar
• Weinberg A, Kroehl ME, Johnson MJ, Hammes A, Reinhold D, Lang N, Levin MJ. Comparative immune responses to licensed herpes zoster vaccines. J Infect Dis. 2018;218(suppl_2):S81–7. doi:10.1093/infdis/jiy383.
   PubMedGoogle Scholar
• Johnson MJ, Liu C, Ghosh D, Lang N, Levin MJ, Weinberg A. Cell-mediated immune responses after administration of the live or the recombinant zoster vaccine: 5-year persistence. J Infect Dis. 2022;225(8):1477–81. doi:10.1093/infdis/jiab580.
   PubMed Web of Science ®Google Scholar
• Schmid DS, Miao C, Leung J, Johnson M, Weinberg A, Levin MJ. Comparative antibody responses to the live-attenuated and recombinant herpes zoster vaccines. J Virol. 2021;95(12):e0024021. doi:10.1128/jvi.00240-21.
   Web of Science ®Google Scholar
• Levin MJ, Kroehl ME, Johnson MJ, Hammes A, Reinhold D, Lang N, Weinberg A. Th1 memory differentiates recombinant from live herpes zoster vaccines. J Clin Invest. 2018;128(10):4429–40. doi:10.1172/jci121484.
   PubMed Web of Science ®Google Scholar
• Schwarz TF, Aggarwal N, Moeckesch B, Schenkenberger I, Claeys C, Douha M, Godeaux O, Grupping K, Heineman TC, Fauqued ML, et al. Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine coadministered with seasonal influenza vaccine in adults aged 50 years or older. J Infect Dis. 2017;216(11):1352–61. doi:10.1093/infdis/jix481.
   PubMed Web of Science ®Google Scholar
• Min JY, Mwakingwe-Omari A, Riley M, Molo LY, Soni J, Girard G, Danier J. The adjuvanted recombinant zoster vaccine co-administered with the 13-valent pneumococcal conjugate vaccine in adults aged ≥50 years: a randomized trial. J Infect. 2022;84(4):490–8. doi:10.1016/j.jinf.2021.12.033.
   PubMed Web of Science ®Google Scholar
• Maréchal C, Lal H, Poder A, Ferguson M, Enweonye I, Heineman TC, Hervé C, Rheault P, Talli J, Wauters D, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥50 years of age: a randomized trial. Vaccine. 2018;36(29):4278–86. doi:10.1016/j.vaccine.2018.05.110.
   PubMed Web of Science ®Google Scholar
• Strezova A, Lal H, Enweonye I, Campora L, Beukelaers P, Segall N, Heineman TC, Schuind AE, Oostvogels L. The adjuvanted recombinant zoster vaccine co-administered with a tetanus, diphtheria and pertussis vaccine in adults aged ≥50 years: a randomized trial. Vaccine. 2019;37(39):5877–85. doi:10.1016/j.vaccine.2019.08.001.
   PubMed Web of Science ®Google Scholar
• Berkowitz EM, Moyle G, Stellbrink HJ, Schürmann D, Kegg S, Stoll M, El Idrissi M, Oostvogels L, Heineman TC, Brockmeyer N, et al. Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study. J Infect Dis. 2015;211(8):1279–87. doi:10.1093/infdis/jiu606.
   PubMed Web of Science ®Google Scholar
• Vink P, Ramon Torrell JM, Sanchez Fructuoso A, Kim SJ, Kim SI, Zaltzman J, Ortiz F, Campistol Plana JM, Fernandez Rodriguez AM, Rebollo Rodrigo H, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in chronically immunosuppressed adults following renal transplant: a phase 3, randomized clinical trial. Clin Infect Dis. 2020;70(2):181–90. doi:10.1093/cid/ciz177.
   PubMed Web of Science ®Google Scholar
• Lindemann M, Baumann C, Wilde B, Gäckler A, Meller L, Horn PA, Krawczyk A, Witzke O. Prospective, longitudinal study on specific cellular immune responses after vaccination with an adjuvanted, recombinant zoster vaccine in kidney transplant recipients. Vaccines (Basel). 2022;10(6):844. doi:10.3390/vaccines10060844.
   PubMed Web of Science ®Google Scholar
• Hirzel C, L’Huillier AG, Ferreira VH, Marinelli T, Ku T, Ierullo M, Miao C, Schmid DS, Juvet S, Humar A, et al. Safety and immunogenicity of adjuvanted recombinant subunit herpes zoster vaccine in lung transplant recipients. Am J Transplant. 2021;21(6):2246–53. doi:10.1111/ajt.16534.
   PubMed Web of Science ®Google Scholar
• L’Huillier AG, Hirzel C, Ferreira VH, Ierullo M, Ku T, Selzner N, Schiff J, Juvet S, Miao C, Schmid DS, et al. Evaluation of recombinant herpes zoster vaccine for primary immunization of varicella-seronegative transplant recipients. Transplantation. 2021;105(10):2316–23. doi:10.1097/tp.0000000000003621.
   PubMed Web of Science ®Google Scholar
• Vink P, Delgado Mingorance I, Maximiano Alonso C, Rubio-Viqueira B, Jung KH, Rodriguez Moreno JF, Grande E, Marrupe Gonzalez D, Lowndes S, Puente J, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: a randomized trial. Cancer. 2019;125(8):1301–12. doi:10.1002/cncr.31909.
   PubMed Web of Science ®Google Scholar
• Muchtar E, Koehler AB, Johnson MJ, Rabe KG, Ding W, Call TG, Leis JF, Kenderian SS, Hayman SR, Wang Y, et al. Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis. Am J Hematol. 2022;97(1):90–8. doi:10.1002/ajh.26388.
   PubMed Web of Science ®Google Scholar
• Koldehoff M, Horn PA, Lindemann M. Cellular immune response after vaccination with an adjuvanted, recombinant zoster vaccine in allogeneic hematopoietic stem cell transplant recipients. Vaccines (Basel). 2022;10(5):809. doi:10.3390/vaccines10050809.
   PubMed Web of Science ®Google Scholar
• Camargo JF, Lin RY, Natori Y, Anderson AD, Alencar MC, Wang TP, Morris MI, Komanduri KV. Reduced immunogenicity of the adjuvanted recombinant zoster vaccine after hematopoietic cell transplant: a pilot study. Blood Adv. 2020;4(19):4618–22. doi:10.1182/bloodadvances.2020002269.
   PubMed Web of Science ®Google Scholar
• Pleyer C, Ali MA, Cohen JI, Tian X, Soto S, Ahn IE, Gaglione EM, Nierman P, Marti GE, Hesdorffer C, et al. Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines. Blood. 2021;137(2):185–9. doi:10.1182/blood.2020008758.
   PubMed Web of Science ®Google Scholar
• Pleyer C, Laing KJ, Ali MA, McClurkan CL, Soto S, Ahn IE, Nierman P, Maddux E, Lotter J, Superata J, et al. BTK inhibitors impair humoral and cellular responses to recombinant zoster vaccine in CLL. Blood Adv. 2022;6(6):1732–40. doi:10.1182/bloodadvances.2021006574.
   PubMed Web of Science ®Google Scholar
• Callegaro A, Burny W, Herve C, Hyung Kim J, Levin MJ, Zahaf T, Cunningham AL, Didierlaurent AM. Association between immunogenicity and reactogenicity: a post hoc analysis of 2 phase 3 studies with the adjuvanted recombinant zoster vaccine. J Infect Dis. 2022;226(11):1943–8. doi:10.1093/infdis/jiab536.
   PubMed Web of Science ®Google Scholar
• Ocran-Appiah J, Boutry C, Hervé C, Soni J, Schuind A, Olsson Å, Anitta A, Novo Marta A, Charles A, Mark A, et al. Safety of the adjuvanted recombinant zoster vaccine in adults aged 50 years or older. A phase IIIB, non-randomized, multinational, open-label study in previous ZOE-50 and ZOE-70 placebo recipients. Vaccine. 2021;39(1):6–10. doi:10.1016/j.vaccine.2020.10.029.
   PubMed Web of Science ®Google Scholar
• López-Fauqued M, Campora L, Delannois F, El Idrissi M, Oostvogels L, De Looze FJ, Diez-Domingo J, Heineman TC, Lal H, McElhaney JE, et al. Safety profile of the adjuvanted recombinant zoster vaccine: pooled analysis of two large randomised phase 3 trials. Vaccine. 2019;37(18):2482–93. doi:10.1016/j.vaccine.2019.03.043.
   PubMed Web of Science ®Google Scholar
• Colindres R, Wascotte V, Brecx A, Clarke C, Hervé C, Kim JH, Levin MJ, Oostvogels L, Zahaf T, Schuind A, et al. Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials. Hum Vaccin Immunother. 2020;16(11):2628–33. doi:10.1080/21645515.2020.1741312.
   PubMed Web of Science ®Google Scholar
• Curran D, Oostvogels L, Heineman T, Matthews S, McElhaney J, McNeil S, Diez-Domingo J, Lal H, Andrews C, Athan E, et al. Quality of life impact of an adjuvanted recombinant zoster vaccine in adults aged 50 years and older. J Gerontol A Biol Sci Med Sci. 2019;74(8):1231–8. doi:10.1093/gerona/gly150.
   PubMed Web of Science ®Google Scholar
• Coplan PM, Schmader K, Nikas A, Chan IS, Choo P, Levin MJ, Johnson G, Bauer M, Williams HM, Kaplan KM, et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain. 2004;5(6):344–56. doi:10.1016/j.jpain.2004.06.001.
   PubMed Web of Science ®Google Scholar
• Schmader KE, Levin MJ, Grupping K, Matthews S, Butuk D, Chen M, Idrissi ME, Fissette LA, Fogarty C, Hartley P, et al. The impact of reactogenicity after the first dose of recombinant zoster vaccine on the physical functioning and quality of life of older adults: an open-label, phase III trial. J Gerontol A Biol Sci Med Sci. 2019;74(8):1217–24. doi:10.1093/gerona/gly218.
   PubMed Web of Science ®Google Scholar
• Schmader KE, Levin MJ, Chen M, Matthews S, Riley ME, Woo W, Hervé C, Grupping K, Schuind AE, Oostvogels L, et al. Impact of reactogenicity after two doses of recombinant zoster vaccine upon physical functioning and quality of life: an open phase III trial in older adults. J Gerontol A Biol Sci Med Sci. 2021;76(3):485–90. doi:10.1093/gerona/glaa127.
   PubMed Web of Science ®Google Scholar
• Curran D, Matthews S, Rowley SD, Young JH, Bastidas A, Anagnostopoulos A, Barista I, Chandrasekar PH, Dickinson M, El Idrissi M, et al. Recombinant zoster vaccine significantly reduces the impact on quality of life caused by herpes zoster in adult autologous hematopoietic stem cell transplant recipients: a randomized placebo-controlled trial (ZOE-HSCT). Biol Blood Marrow Transplant. 2019;25(12):2474–81. doi:10.1016/j.bbmt.2019.07.036.
   PubMed Web of Science ®Google Scholar
• Grupping K, Campora L, Douha M, Heineman TC, Klein NP, Lal H, Peterson J, Vastiau I, Oostvogels L. Immunogenicity and safety of the HZ/su adjuvanted herpes zoster subunit vaccine in adults previously vaccinated with a live attenuated herpes zoster vaccine. J Infect Dis. 2017;216(11):1343–51. doi:10.1093/infdis/jix482.
   PubMed Web of Science ®Google Scholar